Radezolid Controlled-Release Formulation for Microbial Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of pharmaceutical compositions for effective delivery of antimicrobial agents to achieve systemic concentrations against microbial infections poses challenges, as existing formulations may be ineffective or harmful unless properly formulated for in vivo administration.
Innovation Solution
A pharmaceutical composition comprising radezolid or its pharmaceutically acceptable salt, hydroxypropylmethylcellulose polymer, croscarmellose sodium as a disintegrant, a lubricant such as colloidal silicon dioxide or magnesium stearate, and a filler like lactose monohydrate or dicalcium phosphate, optimized to provide a pharmaceutically effective amount of the antimicrobial agent for treating, preventing, or reducing the risk of microbial infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If an antimicrobial agent is formulated for in vivo administration, then therapeutic efficacy is achieved, but formulation complexity increases
Solution Approach 1:
The formulation is segmented into distinct functional components: radezolid as the active antimicrobial agent, hydroxypropylmethylcellulose polymer as the controlled-release matrix, croscarmellose sodium as disintegrant, and lubricants. This segmentation allows each component to perform its specific function optimally while maintaining overall formulation effectiveness.
Solution Approach 2:
The hydroxypropylmethylcellulose polymer acts as an intermediary substance that mediates between the antimicrobial agent and the biological environment. It provides controlled release of radezolid, protecting the active ingredient while ensuring sustained therapeutic concentrations without requiring complex delivery systems.
2Reliability
If the antimicrobial agent is administered to achieve systemic concentrations above MIC, then therapeutic effect is improved, but risk of harmful effects increases
Solution Approach 1:
The hydroxypropylmethylcellulose polymer is pre-formulated to provide controlled release kinetics before administration. This preliminary action ensures that radezolid is released at controlled rates, maintaining systemic concentrations above MIC for sufficient time while preventing toxic peaks, thus reducing harmful effects before they can occur.
Solution Approach 2:
The formulation changes the release rate parameter of the antimicrobial agent through the hydroxypropylmethylcellulose matrix. This parameter modification ensures sustained therapeutic concentrations without excessive peaks, optimizing the balance between efficacy and safety by controlling the temporal profile of drug release.
3Duration of action of moving object
If a controlled-release formulation is used, then duration of action is extended, but manufacturing precision requirements increase
Solution Approach 1:
The hydroxypropylmethylcellulose polymer concentration and molecular weight are optimized to achieve the desired controlled-release profile. By adjusting these parameters within established ranges, the formulation achieves extended duration of action while maintaining manufacturability without requiring excessive precision in the manufacturing process.
Data Source
AI summary
The present invention relates to pharmaceutical compositions useful for administration for treating, preventing, or reducing the risk of microbial infections.